Sales roll out in Europe must have been severely impacted by COVID but its a timing issue not an issue of whether sales will occur. Once the device is approved by domestic pharmaceutical product payment boards (always takes time to get onboard) sales should jump and it looks a takeover target to me.
Sales roll out in Europe must have been severely impacted by...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.001(4.00%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.4¢ | 1.2¢ | $176.4K | 13.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 5353143 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 493343 | 1 |
View Market Depth
| Last trade - 15.45pm 13/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |